CardioVascular BioTherapeutics, Inc. (CVBT/CVBT.OB) Wrap Up:

CardioVascular BioTherapeutics, Inc., a development stage biopharmaceutical company, focuses on developing and marketing protein drug candidates used in the treatment of cardiovascular disease. The company uses an active pharmaceutical ingredient, the 141 acidic human form of fibroblast growth factor-1, in its drug candidates, which facilitates the growth of new blood vessels in the heart tissues and organs with an impaired vascular system. Its products under development include CVBT-141A, a Phase I clinical trial completed product for use in the treatment of severe coronary heart disease; and CVBT-141B, a Phase I clinical trial completed product for the treatment of wound healing; CVBT-141C...